Abstract |
Dipeptidyl peptidase (DPP)-4 inhibitors are a new class of antidiabetic drugs that increase incretin hormone levels to enhance blood sugar level-dependent insulinotropic effects, suppress glucagon action, and reduce bowel motility. These incretin effects are ideal for blood sugar control. However, the safety profile of DPP-4 inhibitors is not yet established. Herein, we present three cases of ileus, considered to be closely related to the use of DPP-4 inhibitors, in diabetic patients. Each of the three patients exhibited some risk of a deficiency in bowel movement; the onset of ileus was within 40 days after strengthened inhibition of DPP-4. The use of a DPP-4 inhibitor could be safe, although the cases presented herein enable us to inform the scientific community to some of the potential adverse effects of the use of DPP-4 inhibitors in select populations.
|
Authors | Keizo Kanasaki, Kazunori Konishi, Ranji Hayashi, Hisakazu Shiroeda, Tomoe Nomura, Atsushi Nakagawa, Takako Nagai, Ai Takeda-Watanabe, Hiroki Ito, Shin-Ichi Tsuda, Munehiro Kitada, Mizue Fujii, Megumi Kanasaki, Makoto Nishizawa, Yasuharu Nakano, Yasuto Tomita, Nobuhiko Ueda, Takeo Kosaka, Daisuke Koya |
Journal | Journal of diabetes investigation
(J Diabetes Investig)
Vol. 4
Issue 6
Pg. 673-5
(Nov 27 2013)
ISSN: 2040-1116 [Print] Japan |
PMID | 24843724
(Publication Type: Journal Article)
|